Moreover, since simultaneous blockade of TIGIT and PD-1 could enhance cytokine production, proliferation and degranulation in CD8+ TILs from melanoma patients, one could surmise that the combination of multiple CSRs based on TIGIT and PD1, each with different signaling moieties may act synergistically [19]. The gene discussed is TIGIT; the disease is melanoma.